Ladenburg Thalmann Financial Services Inc. Acquires 1,551 Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ)

Ladenburg Thalmann Financial Services Inc. lifted its stake in Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 795.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,746 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,551 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Jazz Pharmaceuticals were worth $255,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in shares of Jazz Pharmaceuticals by 11,990.7% during the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after purchasing an additional 866,691 shares during the last quarter. FMR LLC boosted its holdings in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after purchasing an additional 849,348 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Jazz Pharmaceuticals by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after purchasing an additional 410,031 shares during the last quarter. Schroder Investment Management Group bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $52,571,000. Finally, Balyasny Asset Management LLC raised its position in shares of Jazz Pharmaceuticals by 155.8% during the 2nd quarter. Balyasny Asset Management LLC now owns 270,602 shares of the specialty pharmaceutical company’s stock valued at $42,079,000 after buying an additional 164,806 shares in the last quarter. Hedge funds and other institutional investors own 90.73% of the company’s stock.

Several analysts have recently issued reports on JAZZ shares. UBS Group restated a “buy” rating and set a $172.00 target price (down from $175.00) on shares of Jazz Pharmaceuticals in a research report on Monday, September 25th. BMO Capital Markets restated a “buy” rating and set a $196.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 20th. JPMorgan Chase & Co. restated a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 18th. Stifel Nicolaus restated a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, October 26th. Finally, Cowen set a $190.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $181.68.

In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $139.73, for a total value of $1,257,570.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Iain Mcgill sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the completion of the sale, the senior vice president now owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,552 shares of company stock worth $2,399,643. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals plc – (JAZZ) opened at $150.19 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10. Jazz Pharmaceuticals plc – has a one year low of $113.85 and a one year high of $163.75. The stock has a market cap of $8,900.00, a P/E ratio of 24.74, a PEG ratio of 0.80 and a beta of 0.97.

TRADEMARK VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/14/jazz-pharmaceuticals-plc-jazz-shares-bought-by-ladenburg-thalmann-financial-services-inc.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply